NI
SYRE icon

Numeric Investors’s Spyre Therapeutics SYRE Stock Holding History

Numeric Investors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,600
Closed -$190K – 1172
2017
Q3 		$190K Buy
1,600
+20
+1% +$1.88K ﹤0.01% 1040
2017
Q2 		$152K Hold
1,580
– – ﹤0.01% 990
2017
Q1 		$294K Buy
+1,580
New +$223K ﹤0.01% 907

Other funds holding SYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Numeric Investors's SYRE Position: Q4 2017 in Review

Numeric Investors sold out of Spyre Therapeutics (SYRE) in Q4 2017, closing a stake of 1,600 shares — an estimated $190K sold.

Numeric Investors first reported a position in SYRE in Q1 2017 and held it in 3 quarters. The position peaked at $294K in Q1 2017. 31 funds tracked by Wall St. Rank hold SYRE as of Q4 2017.

  • Numeric Investors reported no remaining Spyre Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Numeric Investors sold 1,600 Spyre Therapeutics shares in Q4 2017, an estimated $190K.
  • Numeric Investors first reported a position in Spyre Therapeutics in Q1 2017 and held it in 3 quarters.
  • Numeric Investors's Spyre Therapeutics position peaked at $294K in Q1 2017.
  • 31 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2017.

Based on Numeric Investors's 13F filing for Q4 2017, filed 14 Feb 2018.